Monitoring Polymedica

When shares of PolyMedica (PLMD), trading at 11 1/2 in early November, weakened in recent weeks and hit 5 on Mar. 23, medical analyst Sharon di Stefano of Ryan Beck, an investment firm in Livingston, N.J., contacted not only management but large PolyMedica shareholders to find out why the stock had crashed. She found no fundamental reason to justify the fall. "They weren't selling, and they may in fact be buyers at these levels," says di Stefano. The stock edged up to 6 1/16 the next day.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.